TY - JOUR
T1 - Pulse intravenous cyclophosphamide therapy for dermatologic disorders
AU - Fox, Lindy P.
AU - Pandya, Amit G.
PY - 2000
Y1 - 2000
N2 - Cyclophosphamide is a potent immunosuppressive agent, is a well-established treatment modality for a variety of disorders. Pulse intravenous cyclophosphamide has been shown to be efficacious for several dermatologic disorders, particularly pemphigus vulgaris, with a low incidence of toxicity reported. As reported earlier, studies performed on the use of pulse intravenous cyclophosphamide in the treatment of a variety of dermatology-related diseases strongly suggest that the toxicities frequently noted with the use of oral cyclophosphamide therapy may be significantly less common with pulse intravenous administration of cyclophosphamide. The short follow-up period of patients treated with this modality so far, however, requires constant vigilance for the development of side effects, particularly secondary malignancy. At this time, pulse intravenous cyclophosphamide is a promising treatment modality with an acceptable risk profile for moderate-to-severe dermatologic diseases recalcitrant to standard therapy. Prospective comparative trials are needed to assess further the efficacy and toxicity of this therapy.
AB - Cyclophosphamide is a potent immunosuppressive agent, is a well-established treatment modality for a variety of disorders. Pulse intravenous cyclophosphamide has been shown to be efficacious for several dermatologic disorders, particularly pemphigus vulgaris, with a low incidence of toxicity reported. As reported earlier, studies performed on the use of pulse intravenous cyclophosphamide in the treatment of a variety of dermatology-related diseases strongly suggest that the toxicities frequently noted with the use of oral cyclophosphamide therapy may be significantly less common with pulse intravenous administration of cyclophosphamide. The short follow-up period of patients treated with this modality so far, however, requires constant vigilance for the development of side effects, particularly secondary malignancy. At this time, pulse intravenous cyclophosphamide is a promising treatment modality with an acceptable risk profile for moderate-to-severe dermatologic diseases recalcitrant to standard therapy. Prospective comparative trials are needed to assess further the efficacy and toxicity of this therapy.
UR - http://www.scopus.com/inward/record.url?scp=0033888954&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033888954&partnerID=8YFLogxK
U2 - 10.1016/S0733-8635(05)70194-7
DO - 10.1016/S0733-8635(05)70194-7
M3 - Article
C2 - 10943541
AN - SCOPUS:0033888954
SN - 0733-8635
VL - 18
SP - 459
EP - 473
JO - Dermatologic Clinics
JF - Dermatologic Clinics
IS - 3
ER -